A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer’s disease, who have a specific genetic variant associated with an increased risk of disease progression. “This biomarker study is a key element of our overall Alzheimer’s clinical development program for ALZ‑801,” Susan Abushakra, MD, chief medical officer of Alzheon, the company developing this possible therapy, said in a press release. ALZ-801…
You must be logged in to read/download the full post.
The post First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801 appeared first on BioNewsFeeds.